# Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration

> **NCT01157065** · PHASE2 · COMPLETED · sponsor: **Alcon Research** · enrollment: 99 (actual)

## Conditions studied

- Exudative Age-Related Macular Degeneration

## Interventions

- **DRUG:** AL-78898A
- **DRUG:** Ranibizumab

## Key facts

- **NCT ID:** NCT01157065
- **Lead sponsor:** Alcon Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2013-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01157065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01157065, "Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01157065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*